摘要
利妥昔单抗为人鼠嵌合型单克隆抗体,已被FDA批准用于复发或难治性的CD20阳性的B细胞低度恶性或滤泡型非霍奇金淋巴瘤(NHL)的治疗。它能特异性结合B淋巴细胞表面CD20抗原,杀伤体内的B淋巴细胞。临床主要用于治疗各种一线或二线B细胞NHL,可以单独应用,亦可与化疗药物联合应用,目前还尝试用于慢性淋巴细胞白血病、多发性骨髓瘤、特发行血小板减少性紫癜等的治疗。
The mouse/human chimeric anti-CD20 Moab mabthera（rituximab） has been approved by the US Food and Drug Administration for the treatment of relapsed and refractory advanced follicular non- Hodgkin＇s lymphoma. Rituximab targets the CD20 cell surface protein present on mature B cells and most B- cell malignancies. Rituximab has clinically used for various B-cell lymphomas as either first/second line single or combined regimen with other chemotherapies. Other clinical therapies against chronic lymphocytic leukemia, multiple myeloma, idiopathic thrombocytopenic purpura with rituximab are ongoing in the clinical studies settings.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2005年第12期1481-1485,共5页
Chinese Journal of New Drugs
